Navigation Links
Viruses against cancer
Date:5/4/2010

Particular parvoviruses normally infect rodents, but they are also infectious for human cells. However, they do not cause any disease symptoms in humans. Most importantly, these viruses have an astonishing property: They kill infected tumors cells without causing any damage to healthy tissue. Therefore, scientists in the teams of Jean Rommelaere and Jrg Schlehofer at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been investigating over the past years whether these viruses can be used as weapons against cancer.

Many different viruses have been tested before in cancer therapy, particularly for treating those types of cancer for which there are no effective established treatment methods. The DKFZ researchers realized early on that parvovirus H-1 has important advantages over other viruses. Now they have been the first to prove that malignant glioblastomas regress completely as a result of treatment with these viruses.

The treatment experiments were conducted in rats who had received brain tumors cells by implantation. Once the resulting brain tumors had reached a specified size, the animals were given parvoviruses, either by direct injection into the tumor or via the blood stream. In those animals in which the viruses had been injected directly into the tumor, the tumors shrank visibly after only three days and even disappeared completely in eight of twelve animals treated. The rodents survived without any symptoms, while untreated control animals suffered from severe disease symptoms within three weeks following tumor cell implantation. In the intravenously treated group, tumors regressed completely in six of nine animals. The animals have survived for more than one year now without any symptoms or late side effects of therapy.

The researchers found no infection-related damage in the nervous tissue surrounding the tumor. The viruses did not spread to the whole organism. Although parvovirus DNA was detectable in all organs after several days following virus transfer, this was only for a short time. The viruses had infected healthy cells, but these did not produce a new virus generation. However, in the tumor tissue, the viruses reproduced and viral protein production was detected only in these cells. In rats that did not bear tumors, the viruses did not reproduce. Thus, it appears that the presence of cancer cells is a necessary condition for the parvoviruses to reproduce.

After the positive results of these experiments the DKFZ researchers are convinced that parvoviruses are suitable candidates for use in cancer treatment. Professor Jean Rommelaere summarizes the reasons why: "Parvovirus H-1 does not cause any disease symptoms in humans. Since we are normally not immune against rodent viruses, it is not immediately eliminated by the human immune system after injection. Parvoviruses kill tumors due to natural properties so that their genetic material does not need to be genetically manipulated like herpes viruses, polio viruses or adenoviruses, which have been used in other studies. Moreover, they do not incorporate their genetic material into the host cell's genome, so we need not fear that they might 'accidentally' boost growth-promoting genes."

Rommelaere's colleague, Jrg Schlehofer, adds two more qualities that could be decisive for therapy of glioblastomas, in particular: "Parvoviruses pass the blood brain barrier so that they can be administered via the blood stream. In addition, they reproduce in cancer cells, which is particularly important for successful treatment of glioblastoma with its diffuse growth. Thus, the second generation viruses reach and eliminate even those cancer cells that have already settled at some distance from the primary tumor."

Parvovirus therapy to be tested in clinical trial

The promising results in the animal model have encouraged the DKFZ scientists, jointly with Dr. Karsten Geletneky of the Neurosurgery Department of Heidelberg University, to plan a clinical trial on the treatment of advanced glioblastomas. Glioblastoma is considered the most threatening type of brain tumor; only about half of those affected survive the first year after diagnosis. Even innovative drugs that have been made available recently can prolong survival only marginally. Therefore, new treatment approaches for this type of cancer are urgently needed.

Preparing such a trial is a tremendous effort. Thus, large amounts of virus have to be produced under controlled conditions for toxicological tests. Therefore, even a large institute like DKFZ could not afford financing a transfer of these results into clinical practice. Continuation of viral therapy development was made possible only by funds from Munich-based company Oryx. The company aims to provide funds for the development of therapeutically effective substances into clinically applicable drugs in an early stage.

Many of the required toxicological data have already been obtained and submitted to the drug approval authority by the researchers so that they expect to be able to admit the first patients to the trial by the end of the year. In addition, DKFZ and Oryx have recently signed another agreement: Oryx will also get involved in the development of a parvovirus therapy against pancreatic cancer.


'/>"/>

Contact: Dr. Sibylle Kohlstaedt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. UT Southwestern researchers identify key molecular step to fighting off viruses
2. MIT researchers harness viruses to split water
3. 40 percent of surface disinfectants ineffective in eliminating viruses that cause gastroenteritis
4. New ways to disarm deadly South American hemorrhagic fever viruses
5. Early immune response needed for hit-and-hide cancer viruses
6. A global breakthrough in the study of a protein linked to the spread of viruses
7. Texas A&M Researchers Examine How Viruses Destroy Bacteria
8. Finding the ZIP-code for gene therapy: Scientists imitate viruses to deliver therapeutic genes
9. Microbiologists find defense molecule that senses respiratory viruses
10. K-State researcher finds 1918 flu resulted in current lineage of H1N1 swine influenza viruses
11. Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... 2017 , ... Bacterial biofilms, surface adherent communities of bacteria that are encased ... food poisoning and catheter infections to gum disease and the rejection of medical implants. ... dollars per year, there is currently a paucity of means for preventing their formation ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... ... today that it is exhibiting in booth B2 at the Association for ... May 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit and ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph ... at the Prince Of Wales Private Hospital. The procedure was performed on a ... patient failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc ...
(Date:5/18/2017)... ... May 17, 2017 , ... Cognition Corporation ... has just released version 9.0 of the Cognition Cockpit platform. , “Our whole ... says David Cronin, CEO of Cognition. “We’re thrilled to finally be able to ...
Breaking Biology Technology: